Highlights

• Pro Medicus shares have declined approximately 48.65% over the past year despite continued Business expansion and technology adoption.
• The company reported growth in revenue, profit after tax and new contract activity during FY26.
• AI, cloud adoption and healthcare imaging Demand remain key areas of development.
• Pro Medicus expanded its product ecosystem through cardiology, digital pathology and AI-driven reporting solutions.

Pro Medicus Ltd (ASX:PME) shares have declined approximately 48.65% over the past year and were trading at around $164.33 as of 22 September. The company’s recent updates highlighted continued operational progress, contract activity and expansion of its healthcare imaging technology platform. Pro Medicus reported that FY26 performance included increased revenue, higher profit after tax and its second-largest year for new contracts.

Pro Medicus is a healthcare technology company focused on medical imaging software solutions. Its Visage platform supports diagnostic imaging workflows, including radiology applications, and the company continues to expand into areas such as cardiology, digital pathology and AI-enabled reporting. The company stated that its platform is used by approximately 11% of the US market, including 11 of the top 20 healthcare institutions in the country.

Recent Development

Pro Medicus highlighted a year of continued contract momentum, including six major renewals and a high number of implementations. The company noted that several implementations occurred late in the second half of FY26, with these contracts expected to contribute more fully to transaction Revenue in FY27.

The company continues to focus on AI integration within healthcare imaging. Pro Medicus stated that its position as the radiologist’s desktop provides a platform through which image-based AI solutions can be delivered, either through its own algorithms, research partnerships or third-party algorithms.

Cloud adoption and broader product utilisation have also supported customer expansion. The company highlighted increasing adoption of cloud solutions, customers selecting multiple modules and demand for its full-platform offering, which includes radiology, cardiology and other healthcare imaging capabilities.

Pro Medicus has continued developing additional healthcare solutions. Its digital pathology solution is already in production in Europe, while its AI-driven reporting platform is also in production in Europe and planned for introduction to the US market in the first half of calendar 2027.

Catalysts to Watch

Future growth areas for Pro Medicus include AI adoption, cloud migration, expansion of healthcare modules and implementation of existing contracts. The company expects recently completed implementations to contribute increased transaction revenue as customers move through full-year contribution periods.

The cardiology offering remains another potential growth area, with the company noting that healthcare organisations are increasingly seeking integrated platforms rather than separate specialty-specific viewers and archives.

Pro Medicus is also advancing strategic investments related to healthcare technology and AI. The company highlighted investments in 4D Medical and Echo IQ as opportunities to expand its AI strategy and explore additional technology partnerships.

Sector Context

Pro Medicus operates in the healthcare technology sector, where demand is influenced by digital transformation in healthcare, cloud adoption, increasing medical data volumes and the need for efficient diagnostic workflows. Healthcare providers are increasingly adopting technology solutions that support faster access to medical information and improved workflow management.

Risk and Uncertainty

Pro Medicus faces risks related to technology adoption cycles, healthcare IT competition, regulatory requirements, customer implementation timelines and the pace of AI integration. The company’s growth also depends on maintaining contract wins, renewals and continued adoption of its healthcare software solutions.

Currency movements can also affect reported financial outcomes, as the company generates significant revenue internationally. Pro Medicus noted that foreign exchange movements affected translated revenue and profit during the financial year, with revenue impacted by just under $12 million and NPAT by $9.8 million.

Key Takeaways

Pro Medicus continues to expand its healthcare technology platform through AI development, cloud adoption, contract renewals and new product offerings. While the stock has experienced a yearly decline, the company’s operational focus remains on increasing platform adoption, expanding healthcare applications and converting its contract pipeline into future revenue.